92 related articles for article (PubMed ID: 15925118)
1. A prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ait-Daoud N; Ma JZ; Cornelius JR
Addict Behav; 2005 Jul; 30(6):1077-85. PubMed ID: 15925118
[TBL] [Abstract][Full Text] [Related]
2. Reductions in and relations between "craving" and drinking in a prospective, open-label trial of ondansetron in adolescents with alcohol dependence.
Dawes MA; Johnson BA; Ma JZ; Ait-Daoud N; Thomas SE; Cornelius JR
Addict Behav; 2005 Oct; 30(9):1630-7. PubMed ID: 16084024
[TBL] [Abstract][Full Text] [Related]
3. Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence.
Johnson BA; Ait-Daoud N; Prihoda TJ
Alcohol Clin Exp Res; 2000 May; 24(5):737-42. PubMed ID: 10832917
[TBL] [Abstract][Full Text] [Related]
4. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of cocaine dependence.
Johnson BA; Roache JD; Ait-Daoud N; Javors MA; Harrison JM; Elkashef A; Mojsiak J; Li SH; Bloch DA
Drug Alcohol Depend; 2006 Oct; 84(3):256-63. PubMed ID: 16631323
[TBL] [Abstract][Full Text] [Related]
5. Effects of ondansetron in early- versus late-onset alcoholics: a prospective, open-label study.
Kranzler HR; Pierucci-Lagha A; Feinn R; Hernandez-Avila C
Alcohol Clin Exp Res; 2003 Jul; 27(7):1150-5. PubMed ID: 12878921
[TBL] [Abstract][Full Text] [Related]
6. A pilot double-blind treatment trial of memantine for alcohol dependence.
Evans SM; Levin FR; Brooks DJ; Garawi F
Alcohol Clin Exp Res; 2007 May; 31(5):775-82. PubMed ID: 17378918
[TBL] [Abstract][Full Text] [Related]
7. Ondansetron for reduction of drinking among biologically predisposed alcoholic patients: A randomized controlled trial.
Johnson BA; Roache JD; Javors MA; DiClemente CC; Cloninger CR; Prihoda TJ; Bordnick PS; Ait-Daoud N; Hensler J
JAMA; 2000 Aug 23-30; 284(8):963-71. PubMed ID: 10944641
[TBL] [Abstract][Full Text] [Related]
8. A pilot study of full-dose ondansetron to treat heavy-drinking men withdrawing from alcohol in Brazil.
Corrêa Filho JM; Baltieri DA
Addict Behav; 2013 Apr; 38(4):2044-51. PubMed ID: 23396176
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial.
Galloway GP; Koch M; Cello R; Smith DE
BMC Psychiatry; 2005 Apr; 5():18. PubMed ID: 15804355
[TBL] [Abstract][Full Text] [Related]
10. Combining ondansetron and naltrexone treats biological alcoholics: corroboration of self-reported drinking by serum carbohydrate deficient transferrin, a biomarker.
Ait-Daoud N; Johnson BA; Javors M; Roache JD; Zanca NA
Alcohol Clin Exp Res; 2001 Jun; 25(6):847-9. PubMed ID: 11410720
[TBL] [Abstract][Full Text] [Related]
11. Ondansetron reduces the craving of biologically predisposed alcoholics.
Johnson BA; Roache JD; Ait-Daoud N; Zanca NA; Velazquez M
Psychopharmacology (Berl); 2002 Apr; 160(4):408-13. PubMed ID: 11919668
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.
Spencer TJ; Wilens TE; Biederman J; Weisler RH; Read SC; Pratt R
Clin Ther; 2006 Feb; 28(2):266-79. PubMed ID: 16678648
[TBL] [Abstract][Full Text] [Related]
13. Ondansetron reduces mood disturbance among biologically predisposed, alcohol-dependent individuals.
Johnson BA; Ait-Daoud N; Ma JZ; Wang Y
Alcohol Clin Exp Res; 2003 Nov; 27(11):1773-9. PubMed ID: 14634493
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, placebo-controlled trial of sertraline in depressed adolescent alcoholics: a pilot study.
Deas D; Randall CL; Roberts JS; Anton RF
Hum Psychopharmacol; 2000 Aug; 15(6):461-469. PubMed ID: 12404308
[TBL] [Abstract][Full Text] [Related]
15. A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence.
Johnson BA; Ait-Daoud N; Elkashef AM; Smith EV; Kahn R; Vocci F; Li SH; Bloch DA;
Int J Neuropsychopharmacol; 2008 Feb; 11(1):1-14. PubMed ID: 17470315
[TBL] [Abstract][Full Text] [Related]
16. Botulinum toxin type A as migraine preventive treatment in patients previously failing oral prophylactic treatment due to compliance issues.
Cady R; Schreiber C
Headache; 2008 Jun; 48(6):900-13. PubMed ID: 18047501
[TBL] [Abstract][Full Text] [Related]
17. The role of oral ondansetron in children with vomiting as a result of acute gastritis/gastroenteritis who have failed oral rehydration therapy: a randomized controlled trial.
Roslund G; Hepps TS; McQuillen KK
Ann Emerg Med; 2008 Jul; 52(1):22-29.e6. PubMed ID: 18006189
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking.
Johnson BA; Ait-Daoud N; Seneviratne C; Roache JD; Javors MA; Wang XQ; Liu L; Penberthy JK; DiClemente CC; Li MD
Am J Psychiatry; 2011 Mar; 168(3):265-75. PubMed ID: 21247998
[TBL] [Abstract][Full Text] [Related]
19. The effect of ondansetron, a 5-HT3 receptor antagonist, in chronic fatigue syndrome: a randomized controlled trial.
The GK; Bleijenberg G; Buitelaar JK; van der Meer JW
J Clin Psychiatry; 2010 May; 71(5):528-33. PubMed ID: 20122367
[TBL] [Abstract][Full Text] [Related]
20. A pilot trial of the alpha-1 adrenergic antagonist, prazosin, for alcohol dependence.
Simpson TL; Saxon AJ; Meredith CW; Malte CA; McBride B; Ferguson LC; Gross CA; Hart KL; Raskind M
Alcohol Clin Exp Res; 2009 Feb; 33(2):255-63. PubMed ID: 18945226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
